Mereo BioPharma Group plc
NASDAQ:MREOBiotechnology
Healthcare
$0.32 +9.69%
+$0.03 today
- Market cap
- $51.08M
- Beta
- 0.28
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$0.22
52W Low $0.20High $3.05
Volume 1.26M
Average 3.36M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$30.97M
FY 2025 · Annual
Investing Cash Flow
-$20,000.00
FY 2025 · Annual
Financing Cash Flow
$327,000.00
FY 2025 · Annual
-99.3% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 19.22M | (42.22M) | (29.47M) | (43.25M) | (41.88M) |
| Depreciation & Amortization | 866.47K | 889K | 1.06M | 1.09M | 622K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.46M | 4.77M | 4.92M | 7.39M | 7.6M |
| Change in Working Capital | (2.49M) | (2.35M) | (1.59M) | (369K) | (3.21M) |
| Accounts Receivables | (794.94K) | (3.47M) | 456K | (1.65M) | 1.4M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 617K | (1.26M) | 146K | (1.38M) |
| Other Working Capital | (1.7M) | 498K | (786K) | 1.13M | (3.23M) |
| Other Non-Cash Items | (29.12M) | (9.91M) | 3.94M | 2.31M | 5.9M |
| Operating Cash Flow | (7.07M) | (48.82M) | (21.13M) | (32.83M) | (30.97M) |
| Capital Expenditures | (722.06K) | (13K) | (419K) | (699K) | (20K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 153.86K | 2M | (419K) | 0 | 0 |
| Investing Cash Flow | (568.2K) | 1.99M | (419K) | (699K) | (20K) |
| Debt Repayment | (933.95K) | 0 | (3.19M) | 0 | 0 |
| Common Stock Issued | 105.99M | 0 | 11.61M | 47M | 327.76K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (253.73K) | 200K | 24K | (853K) | (764) |
| Financing Cash Flow | 104.8M | 200K | 7.97M | 46.15M | 327K |
| Effect of Forex Changes | (1.57M) | (12.58M) | 2.82M | (233K) | 1.93M |
| Net Change in Cash | 95.59M | (59.22M) | (10.76M) | 12.38M | (28.81M) |
| Free Cash Flow | (7.79M) | (48.83M) | (21.55M) | (33.53M) | (30.99M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$41.9M
+ D&A$622.0K
+ Stock-Based Comp$7.6M
+ Deferred Tax$0
- Working Capital-$3.2M
+ Other Non-Cash$5.9M
= Operating Cash Flow-$31.0M
- Capex-$20.0K
= Free Cash Flow-$31.0M
Analysis
FY2025 free cash flow is -$31.0M. FCF conversion is 74.0% of net income. Operating cash flow was -$31.0M, with capex of -$20.0K. The largest bridge item is Stock-Based Comp at $7.6M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Aug 19, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 | |
| 10-Q | Quarterly report | Aug 11, 2026 | |
| 8-K | Current report | Aug 11, 2026 | |
| 8-K | Current report | Aug 11, 2026 |
Does MREO generate free cash flow?
Mereo BioPharma Group plc (MREO) generated -$30.99M of free cash flow in fiscal 2025.
How much operating cash flow does MREO produce?
Operating cash flow was -$30.97M, before capital expenditures of $20,000.00.
Continue the stock analysis
Jump to another research area for this company.